Iron overload remains a concern in myelodysplastic syndrome (MDS) patients especially those requiring recurrent blood transfusions. Whether iron chelating therapy (ICT) is beneficial to the long-term survival of myelodysplastic syndrome is still a controversial issue. Therefore, we conducted a systematic review and meta-analysis to clarify the relationship between ICT and long-term survival in patients with MDS. A total of 14 studies involving 7242 participants were identified; the outcomes revealed that for patients with MDS, ICT resulted in a lower risk of mortality compared to those with no ICT (HR 0.57; 95% CI 0.44–0.70; P < 0.001); what is more, ICT led to a lower risk of leukemia transformation (HR 0.70; 95% CI 0.52–0.93; P = 0.016). Results of subgroup analyses based on adequate ICT or any ICT, low/int-1 IPSS or unclassified IPSS and study types indicated that the ICT had a beneficial role in all these groups of patients.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65. https://doi.org/10.1182/blood-2012-03-420489.
Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, et al. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013;88(10):831–7. https://doi.org/10.1002/ajh.23513.
Waszczuk-Gajda A, Madry K, Machowicz R, Drozd-Sokolowska J, Stella-Holowiecka B, Mital A, et al. Red blood cell transfusion dependency and hyperferritinemia are associated with impaired survival in patients diagnosed with myelodysplastic syndromes: results from the first polish MDS-PALG registry. Adv Clin Exp Med Off Org Wroc Med Univ. 2016;25(4):633–41. https://doi.org/10.17219/acem/62397.
Dreyfus F. The deleterious effects of iron overload in patients with myelodysplastic syndromes. Blood Rev. 2008;22(Suppl 2):S29–34. https://doi.org/10.1016/S0268-960X(08)70006-7.
Shammo JM, Komrokji RS. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy. Expert Rev Hematol. 2018;11(7):577–86. https://doi.org/10.1080/17474086.2018.1486188.
Ghoti H, Amer J, Winder A, Rachmilewitz E, Fibach E. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. Eur J Haematol. 2007;79(6):463–7. https://doi.org/10.1111/j.1600-0609.2007.00972.x.
Lu WY, Zhao MF, Rajbhandary S, Xie F, Chai X, Mu J, et al. Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients. Eur J Haematol. 2013;91(3):249–61. https://doi.org/10.1111/ejh.12159.
Chung YJ, Robert C, Gough SM, Rassool FV, Aplan PD. Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome. Leuk Res. 2014;38(1):95–102. https://doi.org/10.1016/j.leukres.2013.07.008.
Pileggi C, Di Sanzo M, Mascaro V, Marafioti MG, Costanzo FS, Pavia M. Role of serum ferritin level on overall survival in patients with myelodysplastic syndromes: results of a meta-analysis of observational studies. PLoS ONE. 2017;12(6):e0179016. https://doi.org/10.1371/journal.pone.0179016.
Carreau N, Tremblay D, Savona M, Kremyanskaya M, Mascarenhas J. Ironing out the details of iron overload in myelofibrosis: lessons from myelodysplastic syndromes. Blood Rev. 2016;30(5):349–56. https://doi.org/10.1016/j.blre.2016.04.003.
Yassin MA, Soliman AT, De Sanctis V, Hussein RM, Al-Okka R, Kassem N, et al. Jadenu((R)) substituting exjade((R)) in iron overloaded beta-thalassemia major (BTM) patients: a preliminary report of the effects on the tolerability, serum ferritin level, liver iron concentration and biochemical profiles. Mediterr J Hematol Infect Dis. 2018;10(1):e2018064. https://doi.org/10.4084/mjhid.2018.064.
Bollig C, Schell LK, Rucker G, Allert R, Motschall E, Niemeyer CM, et al. Deferasirox for managing iron overload in people with thalassaemia. Cochrane Database Syst Rev. 2017;8:7476. https://doi.org/10.1002/14651858.cd007476.pub3.
Karami H, Kosaryan M, Amree AH, Darvishi-Khezri H, Mousavi M. Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusion-dependent beta-thalassemia major. Clin Pract. 2017;7(1):912. https://doi.org/10.4081/cp.2017.912.
Kattamis A, Aydinok Y, Taher A. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes. Eur J Haematol. 2018;101(3):272–82. https://doi.org/10.1111/ejh.13111.
Leitch HA, Buckstein R, Zhu N, Nevill TJ, Yee KWL, Leber B, et al. Iron overload in myelodysplastic syndromes: evidence based guidelines from the Canadian consortium on MDS. Leuk Res. 2018;74:21–41. https://doi.org/10.1016/j.leukres.2018.09.005.
Zeidan AM, Griffiths EA. To chelate or not to chelate in MDS: that is the question! Blood Rev. 2018;32(5):368–77. https://doi.org/10.1016/j.blre.2018.03.002.
Gattermann N. Iron overload in myelodysplastic syndromes (MDS). Int J Hematol. 2018;107(1):55–63. https://doi.org/10.1007/s12185-017-2367-1.
Mitchell M, Gore SD, Zeidan AM. Iron chelation therapy in myelodysplastic syndromes: where do we stand? Expert Rev Hematol. 2013;6(4):397–410. https://doi.org/10.1586/17474086.2013.814456.
Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168–76. https://doi.org/10.1111/j.1600-0609.2007.00985.x.
List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(17):2134–9. https://doi.org/10.1200/jco.2010.34.1222.
Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res. 2010;34(9):1143–50. https://doi.org/10.1016/j.leukres.2010.03.009.
Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, et al. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). Eur J Haematol. 2014;92(6):527–36. https://doi.org/10.1111/ejh.12300.
Mainous AG 3rd, Tanner RJ, Hulihan MM, Amaya M, Coates TD. The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome. Br J Haematol. 2014;167(5):720–3. https://doi.org/10.1111/bjh.13053.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA J Am Med Assoc. 2000;283(15):2008–12.
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647. https://doi.org/10.1136/bmj.g7647.
Leitch HALC, Goodman TA, Wong KK, Wong DHC, Ramadan KM, Rollins MD, Barnett MJ, Galbraith PF, Vickars LM. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin Leuk. 2008;2:205–11.
Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res. 2010;34(7):864–70. https://doi.org/10.1016/j.leukres.2009.12.004.
Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, et al. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. Transfusion. 2010;50(1):190–9. https://doi.org/10.1111/j.1537-2995.2009.02361.x.
Komrokji RS, Al Ali NH, Padron E, Lancet JE, List AF. Impact of iron chelation therapy on overall survival and AML transformation in lower risk MDS patients treated at the Moffitt cancer center. Blood. 2011;118(21):1196–7.
Neukirchen J, Fox F, Kundgen A, Nachtkamp K, Strupp C, Haas R, et al. Improved survival in MDS patients receiving iron chelation therapy—a matched pair analysis of 188 patients from the Dusseldorf MDS registry. Leuk Res. 2012;36(8):1067–70. https://doi.org/10.1016/j.leukres.2012.04.006.
Lyons RM, Marek BJ, Paley C, Esposito J, Garbo L, DiBella N, et al. Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry. Leuk Res. 2014;38(2):149–54. https://doi.org/10.1016/j.leukres.2013.11.004.
Delforge M, Selleslag D, Beguin Y, Triffet A, Mineur P, Theunissen K, et al. Adequate iron chelation therapy for at least 6 months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. Leuk Res. 2014;38(5):557–63. https://doi.org/10.1016/j.leukres.2014.02.003.
Remacha AF, Arrizabalaga B, Villegas A, Duran MS, Hermosin L, de Paz R, et al. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. Ann Hematol. 2015;94(5):779–87. https://doi.org/10.1007/s00277-014-2274-y.
Langemeijer S, De Swart L, Yu G, Smith A, Crouch S, Johnston T, et al. Impact of treatment with iron chelators in lower-risk MDS patients participating in the European leukemianet MDS (EUMDS) registry. Blood. 2016;128(22):3186.
Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ, et al. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. Br J Haematol. 2017;179(1):83–97. https://doi.org/10.1111/bjh.14825.
Wong SA, Leitch HA. Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit? Leuk Res. 2018;64:24–9. https://doi.org/10.1016/j.leukres.2017.11.005.
Angelucci ELJ, Greenberg PL, Depei W, Hou M, Montaño Figueroa E, Rodriguez G, Dong X, Ghosh J, Bornstein O, Garcia-Manero G. Safety and efficacy, including event-free survival, of deferasirox versus placebo in iron-overloaded patients with low- and int-1-risk myelodysplastic syndromes (mds): outcomes from the randomized, double-blind telesto study. Blood. 2018;132(Suppl 1):234.
Zeidan AM, Hendrick F, Friedmann E, Baer MR, Gore SD, Sasane M, et al. Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. J Comp Eff Res. 2015;4(4):327–40. https://doi.org/10.2217/cer.15.20.
Zeidan AM, Giri S, DeVeaux M, Ballas SK, Duong VH. Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes. Ann Hematol. 2019;98(12):339–50. https://doi.org/10.1007/s00277-018-3539-7.
Abrahama I, Al Yami M, Yun S, Kim HJ, Vincelette ND, McBride A, et al. Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: review and pooled analysis of observational studies. Leuk Res. 2017;57:104–8. https://doi.org/10.1016/j.leukres.2017.03.007.
Maurillo L, Breccia M, Buccisano F, Voso MT, Niscola P, Trape G, et al. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a “real-world’ report from two regional Italian registries: gruppo Romano Mielodisplasie and Registro Basilicata. Eur J Haematol. 2015;95(1):52–6. https://doi.org/10.1111/ejh.12476.
Gattermann N, Finelli C, Della Porta M, Fenaux P, Stadler M, Guerci-Bresler A, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica. 2012;97(9):1364–71. https://doi.org/10.3324/haematol.2011.048546.
Nolte F, Hochsmann B, Giagounidis A, Lubbert M, Platzbecker U, Haase D, et al. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol. 2013;92(2):191–8. https://doi.org/10.1007/s00277-012-1594-z.
Goncalves AC, Cortesao E, Oliveiros B, Alves V, Espadana AI, Rito L, et al. Oxidative stress levels are correlated with P15 and P16 gene promoter methylation in myelodysplastic syndrome patients. Clin Exp Med. 2016;16(3):333–43. https://doi.org/10.1007/s10238-015-0357-2.
Di Renzo M, Pasqui AL, Voltolini L, Gotti G, Pompella G, Auteri A. Myelodysplasia and good syndrome A case report. Clin Exp Med. 2008;8(3):171–3. https://doi.org/10.1007/s10238-008-0175-x.
This manuscript was supported by Shaanxi International Scientific Research Cooperation and Exchange Program (Grant Number: 2016KW-020).
Conflict of interest
We declare that we have no conflict of interest.
The study was approved by the Second Affiliated Hospital of Xi’an Jiaotong University.
Informed consent was obtained from all individual participants included in this study in their original studies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Liu, H., Yang, N., Meng, S. et al. Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis. Clin Exp Med 20, 1–9 (2020). https://doi.org/10.1007/s10238-019-00592-5